Weiner AL - Search Results

1

Magnetic resonance imaging detects a specific peptide-protein binding event.

De León-Rodríguez LM, Ortiz A, Weiner AL, Zhang S, Kovacs Z, Kodadek T, Sherry AD. De León-Rodríguez LM, et al. Among authors: weiner al. J Am Chem Soc. 2002 Apr 10;124(14):3514-5. doi: 10.1021/ja025511v. J Am Chem Soc. 2002. PMID: 11929234

2

Inflammatory disease in HLA-B27 transgenic rats.

Taurog JD, Maika SD, Satumtira N, Dorris ML, McLean IL, Yanagisawa H, Sayad A, Stagg AJ, Fox GM, Lê O'Brien A, Rehman M, Zhou M, Weiner AL, Splawski JB, Richardson JA, Hammer RE. Taurog JD, et al. Among authors: weiner al. Immunol Rev. 1999 Jun;169:209-23. doi: 10.1111/j.1600-065x.1999.tb01317.x. Immunol Rev. 1999. PMID: 10450519 Review.

3

TFOS DEWS II iatrogenic report.

Gomes JAP, Azar DT, Baudouin C, Efron N, Hirayama M, Horwath-Winter J, Kim T, Mehta JS, Messmer EM, Pepose JS, Sangwan VS, Weiner AL, Wilson SE, Wolffsohn JS. Gomes JAP, et al. Among authors: weiner al. Ocul Surf. 2017 Jul;15(3):511-538. doi: 10.1016/j.jtos.2017.05.004. Epub 2017 Jul 20. Ocul Surf. 2017. PMID: 28736341 Review.

4

Drug and gene delivery to the back of the eye: from bench to bedside.

Rowe-Rendleman CL, Durazo SA, Kompella UB, Rittenhouse KD, Di Polo A, Weiner AL, Grossniklaus HE, Naash MI, Lewin AS, Horsager A, Edelhauser HF. Rowe-Rendleman CL, et al. Among authors: weiner al. Invest Ophthalmol Vis Sci. 2014 Apr 28;55(4):2714-30. doi: 10.1167/iovs.13-13707. Invest Ophthalmol Vis Sci. 2014. PMID: 24777644 Free PMC article. Review. No abstract available.

5

Advancements in ocular drug delivery.

Weiner AL, Gilger BC. Weiner AL, et al. Vet Ophthalmol. 2010 Nov;13(6):395-406. doi: 10.1111/j.1463-5224.2010.00835.x. Vet Ophthalmol. 2010. PMID: 21182726 Review.

6

Controlled flow-through dissolution methodology: a high-performance system.

Stevens LE, Missel PJ, Weiner AL. Stevens LE, et al. Among authors: weiner al. Pharm Dev Technol. 2008;13(2):135-53. doi: 10.1080/10837450701831179. Pharm Dev Technol. 2008. PMID: 18379905

7

Correspondence regarding levalbuterol and racemic albuterol, July 2004 Supplement.

Weiner AL. Weiner AL. Am J Manag Care. 2005 Jan;11(1):53; author reply 54. Am J Manag Care. 2005. PMID: 15697101 Free article. No abstract available.

8

Response to travoprost in black and nonblack patients with open-angle glaucoma or ocular hypertension.

Netland PA, Robertson SM, Sullivan EK, Silver L, Bergamini MV, Krueger S, Weiner AL, Davis AA; Travoprost Study Groups. Netland PA, et al. Among authors: weiner al. Adv Ther. 2003 May-Jun;20(3):149-63. doi: 10.1007/BF02850202. Adv Ther. 2003. PMID: 12956257 Clinical Trial.

9

Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist.

Hellberg MR, McLaughlin MA, Sharif NA, DeSantis L, Dean TR, Kyba EP, Bishop JE, Klimko PG, Zinke PW, Selliah RD, Barnes G, DeFaller J, Kothe A, Landry T, Sullivan EK, Andrew R, Davis AA, Silver L, Bergamini MV, Robertson S, Weiner AL, Sallee VL. Hellberg MR, et al. Among authors: weiner al. Surv Ophthalmol. 2002 Aug;47 Suppl 1:S13-33. doi: 10.1016/s0039-6257(02)00293-x. Surv Ophthalmol. 2002. PMID: 12204698

10

Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial.

Fellman RL, Sullivan EK, Ratliff M, Silver LH, Whitson JT, Turner FD, Weiner AL, Davis AA; Travoprost Study Group. Fellman RL, et al. Among authors: weiner al. Ophthalmology. 2002 May;109(5):998-1008. doi: 10.1016/s0161-6420(02)01010-2. Ophthalmology. 2002. PMID: 11986110 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

49 results

Search Page